141 related articles for article (PubMed ID: 38619521)
1. [Clinical study of artificial intelligence-guided image fusion assisted transperineal prostate biopsy].
Hu J; Zhao XD; Zhou YL; Dong N; Ma MF; Chen YH; Sheng ZC; Dong J; He CQ; Xu S
Zhonghua Nan Ke Xue; 2023 Aug; 29(8):729-735. PubMed ID: 38619521
[TBL] [Abstract][Full Text] [Related]
2. Prostate cancer detection rate in men undergoing transperineal template-guided saturation and targeted prostate biopsy.
Kaufmann B; Saba K; Schmidli TS; Stutz S; Bissig L; Britschgi AJ; Schaeren E; Gu A; Langenegger N; Sulser T; Eberli D; Keller EX; Hermanns T; Poyet C
Prostate; 2022 Feb; 82(3):388-396. PubMed ID: 34914121
[TBL] [Abstract][Full Text] [Related]
3. Multicentre evaluation of targeted and systematic biopsies using magnetic resonance and ultrasound image-fusion guided transperineal prostate biopsy in patients with a previous negative biopsy.
Hansen NL; Kesch C; Barrett T; Koo B; Radtke JP; Bonekamp D; Schlemmer HP; Warren AY; Wieczorek K; Hohenfellner M; Kastner C; Hadaschik B
BJU Int; 2017 Nov; 120(5):631-638. PubMed ID: 27862869
[TBL] [Abstract][Full Text] [Related]
4. Is targeted magnetic resonance imaging/transrectal ultrasound fusion prostate biopsy enough for the detection of prostate cancer in patients with PI-RADS ≥3: Results of a prospective, randomized clinical trial.
Zhang J; Zhu A; Sun D; Guo S; Zhang H; Liu S; Fu Q; Zhang K
J Cancer Res Ther; 2020; 16(7):1698-1702. PubMed ID: 33565519
[TBL] [Abstract][Full Text] [Related]
5. Comparison of prostate cancer detection rates between magnetic resonance imaging-targeted biopsy and transrectal ultrasound-guided biopsy according to Prostate Imaging Reporting and Data System in patients with PSA ≥4 ng/mL: a systematic review and meta-analysis.
Zhu K; Qin Z; Xue J; Miao C; Tian Y; Liu S; Zhu S; Gu Q; Hou C; Xu A; Yang J; Wang Z
Transl Androl Urol; 2019 Dec; 8(6):741-753. PubMed ID: 32038971
[TBL] [Abstract][Full Text] [Related]
6. Predictors of prostate cancer detection in MRI PI-RADS 3 lesions - Reality of a tertiary center.
Araújo D; Gromicho A; Dias J; Bastos S; Maciel RM; Sabença A; Xambre L
Arch Ital Urol Androl; 2023 Dec; 95(4):11830. PubMed ID: 38117217
[TBL] [Abstract][Full Text] [Related]
7. Multicentre evaluation of magnetic resonance imaging supported transperineal prostate biopsy in biopsy-naïve men with suspicion of prostate cancer.
Hansen NL; Barrett T; Kesch C; Pepdjonovic L; Bonekamp D; O'Sullivan R; Distler F; Warren A; Samel C; Hadaschik B; Grummet J; Kastner C
BJU Int; 2018 Jul; 122(1):40-49. PubMed ID: 29024425
[TBL] [Abstract][Full Text] [Related]
8. Association Between Prostate Imaging Reporting and Data System (PI-RADS) Score for the Index Lesion and Multifocal, Clinically Significant Prostate Cancer.
Stabile A; Dell'Oglio P; De Cobelli F; Esposito A; Gandaglia G; Fossati N; Brembilla G; Cristel G; Cardone G; Deho' F; Losa A; Suardi N; Gaboardi F; Del Maschio A; Montorsi F; Briganti A
Eur Urol Oncol; 2018 May; 1(1):29-36. PubMed ID: 31100225
[TBL] [Abstract][Full Text] [Related]
9. [Diagnostic efficacy of prostate cancer using targeted biopsy with 6-core systematic biopsy for patients with PI-RADS 5].
Liu Y; Yuan CW; Wu JY; Shen Q; Xiao JX; Zhao Z; Wang XY; Li XS; He ZS; Zhou LQ
Beijing Da Xue Xue Bao Yi Xue Ban; 2023 Oct; 55(5):812-817. PubMed ID: 37807733
[TBL] [Abstract][Full Text] [Related]
10. [Analysis of the relationship between PI-RADS scores and the pathological results of targeted biopsy based on MRI].
Wang YM; Shang JW; Dong L; Liang LH; Zhao RZ; Liang C; Wang SQ; Xia W; Cheng G; Hua LX
Zhonghua Zhong Liu Za Zhi; 2023 Nov; 45(11):942-947. PubMed ID: 37968079
[No Abstract] [Full Text] [Related]
11. A Prospective Comparison of Transrectal Standard, Cognitive, Transperineal Fusion, and Mapping Prostate Biopsy for Cancer Detection.
Petov V; Bazarkin A; Morozov A; Taratkin M; Ganzha T; Danilov S; Chernov Y; Chinenov D; Rzayev R; Suvorov A; Amosov A; Fajkovic H; Enikeev D; Krupinov G
J Endourol; 2023 Aug; 37(8):940-947. PubMed ID: 37294206
[No Abstract] [Full Text] [Related]
12. Comparison of free-hand transperineal mpMRI/TRUS fusion-guided biopsy with transperineal 12-core systematic biopsy for the diagnosis of prostate cancer: a single-center prospective study in China.
Zhang Q; Wang W; Zhang B; Shi J; Fu Y; Li D; Guo S; Zhang S; Huang H; Jiang X; Zhou W; Guo H
Int Urol Nephrol; 2017 Mar; 49(3):439-448. PubMed ID: 28005230
[TBL] [Abstract][Full Text] [Related]
13. Targeted multiparametric magnetic resonance imaging/transrectal ultrasound-guided (mpMRI/TRUS) fusion prostate biopsy versus systematic random prostate biopsy: A comparative real-life study.
Pham THN; Schulze-Hagen MF; Rahnama'i MS
Cancer Rep (Hoboken); 2024 Feb; 7(2):e1962. PubMed ID: 38217298
[TBL] [Abstract][Full Text] [Related]
14. Systematic versus Targeted Magnetic Resonance Imaging/Ultrasound Fusion Prostate Biopsy among Men with Visible Lesions.
Patel HD; Koehne EL; Shea SM; Fang AM; Gorbonos A; Quek ML; Flanigan RC; Goldberg A; Rais-Bahrami S; Gupta GN
J Urol; 2022 Jan; 207(1):108-117. PubMed ID: 34428091
[TBL] [Abstract][Full Text] [Related]
15. Not All Multiparametric Magnetic Resonance Imaging-targeted Biopsies Are Equal: The Impact of the Type of Approach and Operator Expertise on the Detection of Clinically Significant Prostate Cancer.
Stabile A; Dell'Oglio P; Gandaglia G; Fossati N; Brembilla G; Cristel G; Dehò F; Scattoni V; Maga T; Losa A; Gaboardi F; Cardone G; Esposito A; De Cobelli F; Del Maschio A; Montorsi F; Briganti A
Eur Urol Oncol; 2018 Jun; 1(2):120-128. PubMed ID: 31100235
[TBL] [Abstract][Full Text] [Related]
16. Analysis of PI-RADS 4 cases: Management recommendations for negatively biopsied patients.
Ullrich T; Arsov C; Quentin M; Laqua N; Klingebiel M; Martin O; Hiester A; Blondin D; Rabenalt R; Albers P; Antoch G; Schimmöller L
Eur J Radiol; 2019 Apr; 113():1-6. PubMed ID: 30927932
[TBL] [Abstract][Full Text] [Related]
17. Prostate cancer detection on transrectal ultrasonography-guided random biopsy despite negative real-time magnetic resonance imaging/ultrasonography fusion-guided targeted biopsy: reasons for targeted biopsy failure.
Cash H; Günzel K; Maxeiner A; Stephan C; Fischer T; Durmus T; Miller K; Asbach P; Haas M; Kempkensteffen C
BJU Int; 2016 Jul; 118(1):35-43. PubMed ID: 26384851
[TBL] [Abstract][Full Text] [Related]
18. [Real-time MRI/US fusion-guided biopsy improves detection rates of prostate cancer in pre-biopsied patients].
Maxeiner A; Fischer T; Stephan C; Cash H; Slowinski T; Kilic E; Durmus T
Aktuelle Urol; 2014 May; 45(3):197-203. PubMed ID: 24902069
[TBL] [Abstract][Full Text] [Related]
19. Transperineal Versus Transrectal MRI/TRUS Fusion Targeted Biopsy: Detection Rate of Clinically Significant Prostate Cancer.
Pepe P; Garufi A; Priolo G; Pennisi M
Clin Genitourin Cancer; 2017 Feb; 15(1):e33-e36. PubMed ID: 27530436
[TBL] [Abstract][Full Text] [Related]
20. A prospective multi-center randomized comparative trial evaluating outcomes of transrectal ultrasound (TRUS)-guided 12-core systematic biopsy, mpMRI-targeted 12-core biopsy, and artificial intelligence ultrasound of prostate (AIUSP) 6-core targeted biopsy for prostate cancer diagnosis.
Wang X; Xie Y; Zheng X; Liu B; Chen H; Li J; Ma X; Xiang J; Weng G; Zhu W; Wang G; Fang Y; Cheng H; Xie L
World J Urol; 2023 Mar; 41(3):653-662. PubMed ID: 35852595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]